365 related articles for article (PubMed ID: 26501108)
41. Selinexor, selective inhibitor of nuclear export: Unselective bullet for blood cancers.
Benkova K; Mihalyova J; Hajek R; Jelinek T
Blood Rev; 2021 Mar; 46():100758. PubMed ID: 32972802
[TBL] [Abstract][Full Text] [Related]
42. Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma.
Gandhi UH; Senapedis W; Baloglu E; Unger TJ; Chari A; Vogl D; Cornell RF
Clin Lymphoma Myeloma Leuk; 2018 May; 18(5):335-345. PubMed ID: 29610030
[TBL] [Abstract][Full Text] [Related]
43. Heterozygous mutation of cysteine528 in XPO1 is sufficient for resistance to selective inhibitors of nuclear export.
Neggers JE; Vanstreels E; Baloglu E; Shacham S; Landesman Y; Daelemans D
Oncotarget; 2016 Oct; 7(42):68842-68850. PubMed ID: 27634897
[TBL] [Abstract][Full Text] [Related]
44. A first-in-class inhibitor of HSP110 to potentiate XPO1-targeted therapy in primary mediastinal B-cell lymphoma and classical Hodgkin lymphoma.
Durand M; Cabaud Gibouin V; Duplomb L; Salmi L; Caillot M; Sola B; Camus V; Jardin F; Garrido C; Jego G
J Exp Clin Cancer Res; 2024 May; 43(1):148. PubMed ID: 38773631
[TBL] [Abstract][Full Text] [Related]
45. Exportin 1 inhibition attenuates nuclear factor-kappaB-dependent gene expression.
Walsh MD; Hamiel CR; Banerjee A; Cheng AM; Escobar G; McIntyre RC
Shock; 2008 Feb; 29(2):160-6. PubMed ID: 17693924
[TBL] [Abstract][Full Text] [Related]
46. Verdinexor (KPT-335), a Selective Inhibitor of Nuclear Export, Reduces Respiratory Syncytial Virus Replication
Jorquera PA; Mathew C; Pickens J; Williams C; Luczo JM; Tamir S; Ghildyal R; Tripp RA
J Virol; 2019 Feb; 93(4):. PubMed ID: 30541831
[TBL] [Abstract][Full Text] [Related]
47. Salicylates enhance CRM1 inhibitor antitumor activity by induction of S-phase arrest and impairment of DNA-damage repair.
Abeykoon JP; Wu X; Nowakowski KE; Dasari S; Paludo J; Weroha SJ; Hu C; Hou X; Sarkaria JN; Mladek AC; Phillips JL; Feldman AL; Ravindran A; King RL; Boysen J; Stenson MJ; Carr RM; Manske MK; Molina JR; Kapoor P; Parikh SA; Kumar S; Robinson SI; Yu J; Boughey JC; Wang L; Goetz MP; Couch FJ; Patnaik MM; Witzig TE
Blood; 2021 Jan; 137(4):513-523. PubMed ID: 33507295
[TBL] [Abstract][Full Text] [Related]
48. XPO1-dependent nuclear export as a target for cancer therapy.
Azizian NG; Li Y
J Hematol Oncol; 2020 Jun; 13(1):61. PubMed ID: 32487143
[TBL] [Abstract][Full Text] [Related]
49. Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents.
Turner JG; Dawson J; Cubitt CL; Baz R; Sullivan DM
Semin Cancer Biol; 2014 Aug; 27():62-73. PubMed ID: 24631834
[TBL] [Abstract][Full Text] [Related]
50. Novel inhibitors of nuclear transport cause cell cycle arrest and decrease cyst growth in ADPKD associated with decreased CDK4 levels.
Tan M; Wettersten HI; Chu K; Huso DL; Watnick T; Friedlander S; Landesman Y; Weiss RH
Am J Physiol Renal Physiol; 2014 Dec; 307(11):F1179-86. PubMed ID: 25234309
[TBL] [Abstract][Full Text] [Related]
51. Inhibition of the CRM1-mediated nucleocytoplasmic transport by N-azolylacrylates: structure-activity relationship and mechanism of action.
Van Neck T; Pannecouque C; Vanstreels E; Stevens M; Dehaen W; Daelemans D
Bioorg Med Chem; 2008 Nov; 16(21):9487-97. PubMed ID: 18835718
[TBL] [Abstract][Full Text] [Related]
52. Association of XPO1 Overexpression with NF-κB and Ki67 in Colorectal Cancer.
Aladhraei M; Kassem Al-Thobhani A; Poungvarin N; Suwannalert P
Asian Pac J Cancer Prev; 2019 Dec; 20(12):3747-3754. PubMed ID: 31870117
[TBL] [Abstract][Full Text] [Related]
53. Molecular mechanism and therapeutic implications of selinexor (KPT-330) in liposarcoma.
Garg M; Kanojia D; Mayakonda A; Said JW; Doan NB; Chien W; Ganesan TS; Chuang LS; Venkatachalam N; Baloglu E; Shacham S; Kauffman M; Koeffler HP
Oncotarget; 2017 Jan; 8(5):7521-7532. PubMed ID: 27893412
[TBL] [Abstract][Full Text] [Related]
54. Targeting the nuclear transport machinery by rational drug design.
Mao L; Yang Y
Curr Pharm Des; 2013; 19(12):2318-25. PubMed ID: 23082981
[TBL] [Abstract][Full Text] [Related]
55. The myxobacterial metabolite ratjadone A inhibits HIV infection by blocking the Rev/CRM1-mediated nuclear export pathway.
Fleta-Soriano E; Martinez JP; Hinkelmann B; Gerth K; Washausen P; Diez J; Frank R; Sasse F; Meyerhans A
Microb Cell Fact; 2014 Jan; 13():17. PubMed ID: 24475978
[TBL] [Abstract][Full Text] [Related]
56. Nucleo-cytoplasmic transport as a therapeutic target of cancer.
Gravina GL; Senapedis W; McCauley D; Baloglu E; Shacham S; Festuccia C
J Hematol Oncol; 2014 Dec; 7():85. PubMed ID: 25476752
[TBL] [Abstract][Full Text] [Related]
57. HIV-1 Vif's Capacity To Manipulate the Cell Cycle Is Species Specific.
Evans EL; Becker JT; Fricke SL; Patel K; Sherer NM
J Virol; 2018 Apr; 92(7):. PubMed ID: 29321323
[TBL] [Abstract][Full Text] [Related]
58. HIV-1 Nef-associated Factor 1 Enhances Viral Production by Interacting with CRM1 to Promote Nuclear Export of Unspliced HIV-1 gag mRNA.
Ren XX; Wang HB; Li C; Jiang JF; Xiong SD; Jin X; Wu L; Wang JH
J Biol Chem; 2016 Feb; 291(9):4580-8. PubMed ID: 26733199
[TBL] [Abstract][Full Text] [Related]
59. Cooperativity among Rev-associated nuclear export signals regulates HIV-1 gene expression and is a determinant of virus species tropism.
Aligeti M; Behrens RT; Pocock GM; Schindelin J; Dietz C; Eliceiri KW; Swanson CM; Malim MH; Ahlquist P; Sherer NM
J Virol; 2014 Dec; 88(24):14207-21. PubMed ID: 25275125
[TBL] [Abstract][Full Text] [Related]
60. Antitumor effects of a novel chromosome region maintenance 1 (CRM1) inhibitor on non-small cell lung cancer cells in vitro and in mouse tumor xenografts.
Wang S; Han X; Wang J; Yao J; Shi Y
PLoS One; 2014; 9(3):e89848. PubMed ID: 24595136
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
